Last reviewed · How we verify

Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence

Ankylosing Spondylitis (Immunology & Inflammation) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Immunology & Inflammation 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ankylosing Spondylitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Taltz ixekizumab Eli Lilly Interleukin-17A antagonist Interleukin 17A (IL-17A) cytokine 2016-01-01
Cosentyx secukinumab Novartis IL-17A antagonist Interleukin-17A (IL-17A) 2015-01-01
Simponi GOLIMUMAB Centocor Ortho Biotech Inc Tumor Necrosis Factor Blocker [EPC] Tumor necrosis factor 2009-01-01
Cimzia CERTOLIZUMAB PEGOL UCB Tumor Necrosis Factor Blocker [EPC] TNFα 2008-01-01
Abrilada Adalimumab-Afzb AbbVie TNF blocker Tumor necrosis factor-alpha (TNF-alpha) 2002-01-01
Humira ADALIMUMAB AbbVie TNF blocker Tumor Necrosis Factor-alpha (TNF-alpha) 2002-01-01
Tnkase TENECTEPLASE Roche fibrin 2000-01-01
Celebrex celecoxib Pfizer Inc. (originally Searle/Pharmacia) Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Remicade Infliximab-Dyyb Johnson & Johnson TNF blocker Tumor Necrosis Factor alpha (TNFα) 1998-01-01
Enbrel etanercept Immunex Tumor Necrosis Factor Blocker [EPC] Tumor necrosis factor 1998-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 9 drugs in Ankylosing Spondylitis
  2. Pfizer · 8 drugs in Ankylosing Spondylitis
  3. Johnson & Johnson · 3 drugs in Ankylosing Spondylitis
  4. AbbVie · 2 drugs in Ankylosing Spondylitis
  5. Generic (originally Schering) · 2 drugs in Ankylosing Spondylitis
  6. Eli Lilly · 1 drug in Ankylosing Spondylitis
  7. Generic (originally Upjohn/Pfizer) · 1 drug in Ankylosing Spondylitis
  8. Centocor Ortho Biotech Inc · 1 drug in Ankylosing Spondylitis
  9. Generic (originally Syntex) · 1 drug in Ankylosing Spondylitis
  10. BOEHRINGER INGELHEIM · 1 drug in Ankylosing Spondylitis
  11. Generic (originally Merck/Upjohn) · 1 drug in Ankylosing Spondylitis
  12. Generic (originally Merck) · 1 drug in Ankylosing Spondylitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ankylosing Spondylitis:

Cite this brief

Drug Landscape (2026). Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ankylosing-spondylitis. Accessed 2026-05-15.

Related